Germany’s Merck will regain exclusive worldwide rights to develop, manufacture and commercialize the anti-programmed death ligand-1 (PD-L1) antibody Bavencio (avelumab)...
16.06.2017
- US biotechnology group Genentech, part of Roche, is handing back rights to NewLink Genetics’ IDO inhibitor GDC-0919 (navoximod), an investigational cancer treatment. Genentech...
18.04.2017
- The US Food and Drug Administration (FDA) has approved NuvOx Pharma’s application to proceed with Phase 2 clinical trials for an Investigational New Drug (IND) to initiate a Phase...
22.02.2017
- Chinese drugmaker Qilu Pharmaceutical has introduced a new targeted therapy generic cancer medicine, geftinib, which is claimed to be effective against non-small cell lung cancer...
14.07.2016
- The US Food and Drug Administration has ordered Juno Therapeutics to suspend its Phase II immunotherapy trials with adult patients suffering from relapsed or refractory B cell...
23.05.2016
- Genentech has won an accelerated approval from the US Food and Drug Administration (FDA) for bladder cancer treatment Tecentriq. The immunotherapy has been cleared to treat...
29.10.2015
- The US Food and Drug Administration (FDA) has approved, with reservations, the new pancreatic cancer drug Onivyde manufactured by US drugmaker Merrimack for use in combination with...
06.08.2015
- European regulatory authorities have approved the $15.2 billion takeover of injectable drug and infusion device maker Hospira by US drugmaker Pfizer, subject to certain conditions...
